Choreo LLC Boosts Stock Position in Certara, Inc. (NASDAQ:CERT)

Choreo LLC raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 25.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,582 shares of the company’s stock after purchasing an additional 10,118 shares during the quarter. Choreo LLC’s holdings in Certara were worth $533,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in Certara by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after purchasing an additional 975 shares during the period. SG Americas Securities LLC grew its position in shares of Certara by 24.2% in the 3rd quarter. SG Americas Securities LLC now owns 20,260 shares of the company’s stock worth $237,000 after buying an additional 3,948 shares during the period. Handelsbanken Fonder AB grew its position in shares of Certara by 46.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 22,300 shares of the company’s stock worth $261,000 after buying an additional 7,100 shares during the period. Kopion Asset Management LLC bought a new position in shares of Certara in the 3rd quarter worth about $4,457,000. Finally, Blue Trust Inc. lifted its position in Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after acquiring an additional 2,076 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Trading Down 1.0 %

Certara stock opened at $13.86 on Wednesday. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The business’s fifty day moving average is $11.90 and its 200 day moving average is $11.70. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market capitalization of $2.23 billion, a PE ratio of -69.30, a price-to-earnings-growth ratio of 9.33 and a beta of 1.57.

Analyst Ratings Changes

A number of equities analysts have weighed in on CERT shares. Barclays decreased their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.